Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung

DC Doval1
K Prabhash2
S Patil3
H Chatuvedi4
C Goswami5
AK Vaid6
S Desai2
S Dut7
VH Veldore8
N Jambhekar2
A Mehta1
D Hazarika8
S Azam1
S Gawande9
S Gupta10

1Rajiv Gandhi Cancer Institute and Research Centre, New Delhi,
2Tata Memorial Hospital, Mumbai,
3Bangalore Institute of Oncology, HCG Group, Bengaluru,
4Max Super Speciality Hospital, New Delhi,
5B P Poddar Hospital, Kolkata,
6Medanta The Medicity, Gurgoan,
7Oncquest Laboratories Ltd., New Delhi,
8Triesta Reference Laboratory, HCG Group, Bengaluru,
9Pfizer India Ltd., Mumbai,
10Catalyst Clinical Services Pvt. Ltd., New Delhi, India

Background: Mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a common feature observed in lung adenocarcinoma. A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the intracellular domain of anaplastic lymphoma kinase (ALK), named EML4-ALK, has been identified in a subset of non-small-cell lung cancer (NSCLC) tumors. The objective of this study was to determine the prevalence of EGFR mutations and EML4-ALK fusions in Indian patients with NSCLC (adenocarcinoma) as well as evaluate their clinical characteristics.

Patients and methods: Patients with NSCLC, adenocarcinoma histology, whose tumors had been tested for EGFR mutational status, were considered for this study. ALK gene rearrangement was detected by fluorescence in situ hybridization using the Vysis ALK Break Apart Rearrangement Probe Kit. ALK mutation was tested in samples that were negative for EGFR mutation.

Results: A total of 500 NSCLC adenocarcinoma patients were enrolled across six centers. There were 337 (67.4%) men and 163 (32.6%) women with a median age of 58 years. One hundred and sixty-four (32.8%) blocks were positive for EGFR mutations, whereas 336 (67.2%) were EGFR wild-type. Of the 336 EGFR-negative blocks, EML4-ALK fusion gene was present in 15 (4.5%) patients, whereas 321 (95.5%) tumors were EML4-ALK negative. The overall incidence of EML4-ALK fusion gene was 3% (15/500).

Conclusion: The incidence of EGFR mutations (33%) in this Indian population is close to the reported incidence in Asian patients. EML4-ALK gene fusions are present in lung adenocarcinomas from Indian patients, and the 3% incidence of EML4-ALK gene fusion in EGFR mutation-negative cases is similar to what has been observed in other Western and Asian populations. The mutual exclusivity of EML4-ALK and EGFR mutations suggests implementation of biomarker testing for tumors harboring ALK rearrangements in order to identify patients that can benefit from newer targeted therapies.

Keywords: NSCLC, Crizotinib, Vysis ALK Break Apart Rearrangement Probe Kit

Introduction

Lung cancer is one of the leading causes of cancer-related death in many parts of the world, including India. The overall 5-year survival rate remains at 15% despite significant improvements in the detection and treatment of lung cancer.1 Treatment outcomes using various chemotherapy (eg, taxane, platinum, gemcitabine, vinorelbine, pemetrexed) remain poor for advanced non-small-cell lung cancer (NSCLC).2 Adenocarcinoma is the most commonly occurring form of NSCLC and usually presents at an advanced stage with limited treatment options.

The introduction of targeted therapies into the treatment of NSCLC has improved survival of patients. However, it needs an accurate histological classification as
well as testing of tumors for biomarkers that are predictive of response. Activating mutations in exons 18–21 of the tyrosine kinase domain of the gene for epidermal growth factor receptor (EGFR) are known to correlate with a high likelihood of response to EGFR tyrosine kinase inhibitors (TKIs), and these findings have paved the way for a new era of personalized treatment for NSCLC.3,4

Recently, a fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the intracellular domain of anaplastic lymphoma kinase (ALK), named EML4-ALK, has been identified in some NSCLC tumors.5,6 EML4 ALK fusion protein, when inhibited by ALK and c met inhibitors in a selected subset of patients, has shown response rates of more than 60%.7

In an East Asian population, the EML4-ALK fusion gene positivity was found to be 5%, mostly in young patients who were never-smokers.8 However, a higher incidence of ALK mutations was reported in Chinese NSCLC patients, particularly in those with adenocarcinoma lacking EGFR/KRAS mutation. EML4-ALK and EGFR mutations were mutually exclusive, suggesting that ALK mutations may be an important oncogenic factor and a potential therapeutic target in EGFR wild-type lung cancer.9

An oral ATP-competitive TKI of ALK and c-MET, crizotinib (PF-02341066), has shown impressive clinical activity in advanced NSCLCs, especially in tumors harboring ALK rearrangements. An impressive response rate of 57% and 72% progression-free survival were seen in an expanded cohort of 86 patients treated with crizotinib 250 mg twice daily. All these patients were negative for EGFR mutation and amplification of MET, another target for crizotinib, which suggests the therapeutic effect through inhibition of ALK.9 Treatment with crizotinib has been associated with higher 1- and 2-year overall survival, of 77% and 64%, respectively, in patients with advanced NSCLC.10 Crizotinib has been reported to be safe, with preliminary evidence of improved symptoms and clinically meaningful antitumor activity in patients with pretreated ALK-rearranged NSCLC.11 In a Phase III, open-label trial comparing crizotinib with chemotherapy in locally advanced or metastatic ALK-positive lung cancer patients, crizotinib demonstrated a median progression-free survival of 7.7 months, as compared to 3 months in the chemotherapy group (P<0.001). The response rates were 65% with crizotinib compared to 20% in the chemotherapy group (P<0.001).12

Various studies of NSCLC patients of Indian ethnicity have reported the presence of EGFR mutations in the range of 23%–44%.13-15 However, there is only one published report from India on EML 4 ALK mutations, with a limited number of patients.16 Although the presence of EML 4 ALK mutation seems to be mutually exclusive of the presence of EGFR or KRAS mutations in NSCLC, there are a few reports of concurrent existence of both the mutations.17-19 The present study was carried out to detect the prevalence of EGFR mutations and EML4-ALK fusions in EGFR mutation-negative cases of NSCLC (adenocarcinoma) as well as to evaluate the clinical characteristics of EGFR mutations and EML4-ALK fusions in EGFR mutation-negative cases of NSCLC.

Materials and methods

Patients with NSCLC, adenocarcinoma histology, whose tumors had been tested for EGFR mutational status by the amplification-refractory mutation system without enrichment of tumor samples during the period 2010 to 2014, were considered for this study. Stored tissue blocks from six centers were used for this study. Permission was obtained from the ethics committee at each center before the start of the study. Clinical characteristics and treatment details were collected from the patient’s medical records in a de-identified manner. Formalin-fixed, paraffin-embedded tissue blocks were used for the mutation analysis. ALK mutation was tested in samples that were negative for EGFR mutation. ALK gene rearrangement was detected by fluorescence in situ hybridization (FISH) using the Vysis ALK Break Apart Rearrangement Probe Kit (Abbott Molecular, Abbott Park, IL, USA), which identifies all rearrangements of ALK irrespective of other fusion partners.

The Break Apart Rearrangement Probe contained two differently labeled probes on opposite sides of the breakpoint of the ALK gene. A SpectrumOrange (red) labeled 250 kb probe at the 3′ end of ALK and a SpectrumGreen (green) labeled 300 kb probe at the 5′ end of ALK. Sections of 4–6 μm thickness of formalin-fixed, paraffin-embedded tissue were cut and placed onto slides precoated with poly-L-lysine. The slides were deparaffinized, dehydrated, and then put into 10 mM HCl. After drying the slides, they were rinsed with 2.5% sodium thiocyanate solution and steamed in a microwave for 2 minutes. Next, the slides were put into 10 mM sodium citrate buffer and boiled in the microwave for 4 minutes. The slides were immersed in a pepsin–HCl solution at 37°C for 25 minutes and then dehydrated. The probe mixture was added to the slide, the cover slip applied, the edges sealed, and the slide placed in a hybridizer at 80°C for 5 minutes to denature the probe. The hybridizer was sealed and the slides were incubated inside it at 37°C for 16–20 hours to allow hybridization. Post–hybridization washes with saline sodium citrate were given and 4,6-diamidino-2-phenylindole (DAPI) counterstain was applied. The signals for each probe...
were evaluated under a fluorescence microscope using an oil immersion objective.

There were two patterns of ALK rearrangement. One was break-apart, where the red and green signals were split, and the distance between these two signals was ≥2 signal diameters.16 In the other pattern, the green signal was lost, and only isolated or single red signals (3′ ALK) were observed, and these denote deletion in the 5′ ALK region in association with 2p inversion.16 A minimum of 50 tumor cells were counted, and cases were considered positive for ALK rearrangement when >15% of the tumor cells showed split signals or single red signals; the rest of the cases were classified as ALK FISH negative.20–22 While scoring, normal lung tissue and lymphocyte nuclei were not counted. If no signals were detected, the test was repeated (if enough tissue was present). When the repeat test also showed no signals, the result of “test uninterpretable” was issued and the cause of uninterpretability reported. The FISH results were evaluated and the reasons for uninterpretable results investigated.

Statistical analysis was performed using Pearson’s chi-squared or Fisher’s exact test – whichever was appropriate for categorical variables. Logistic regression was performed to compare the study groups. A two-sided \( P<0.05 \) was considered significant. Binary logistic regression with a single independent variable was performed; therefore, statistical correction has not been applied to the \( P \)-values reported in this paper. Statistical analysis was performed using SAS software (v 9.3; SAS Institute Inc., Cary, NC, USA).

**Results**

We included 500 NSCLC adenocarcinoma patients in this study across six centers. There were 337 (67.4%) men and 163 (32.6%) women with a median age of 58 years (range 21 to 90 years). Of the 500 patients, 250 (50%) were never-smokers and 357 (71.4%) had stage IV disease at the time of initial diagnosis. Baseline patient characteristics are presented in Table 1.

The results of molecular testing are shown in Table 2 and Figure 1. One hundred and sixty-four (32.8%) blocks were positive for EGFR mutations, whereas 336 (67.2%) were EGFR wild-type. Of the 336 EGFR-negative blocks, EML4-ALK fusion gene was present in 15 (4.5%) patients, whereas 321 (95.5%) tumors were EML4-ALK negative. The overall incidence of EML4-ALK fusion gene was 3% (15/500). Chemotherapy alone or in combination with radiotherapy and oral targeted therapy was the foremost treatment modality adopted to treat these patients.

The association of each of the individual factors with regard to EGFR and EML4-ALK fusion gene mutation is shown in Table 3. While sex and cigarette smoking were significantly associated with EGFR mutation \( (P<0.05) \) the EML4-ALK fusion gene mutation showed a significant association with sex and age \( (P<0.05) \). There was a borderline association of cigarette smoking with EML4-ALK fusion gene mutation \( (P=0.053) \).

Table 4 presents the distribution of EGFR and EML4-ALK gene mutations across the study groups.

**Discussion**

The last decade has been an exciting period for pulmonary oncology research, wherein targeted therapies have improved median overall survival for patients with metastatic NSCLC to more than 1 year.3 Certain clinical subgroups, namely the never-smoking and minimal former-smoking patients, have seen even greater survival advantage. The uncontested benefit of EGFR TKIs for patients with EGFR activating mutations has clearly demonstrated the feasibility and power of tumor

---

**Table 1** Summary of patient demographics and tumor characteristics (N=500)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years (range)</td>
<td>58 (21–90)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>337 (67.4%)</td>
</tr>
<tr>
<td>Female</td>
<td>163 (32.6%)</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
</tr>
<tr>
<td>Smokers</td>
<td>164 (32.8%)</td>
</tr>
<tr>
<td>Never-smokers</td>
<td>250 (50%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>86 (17.2%)</td>
</tr>
<tr>
<td>Basis of diagnosis</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td>500 (100%)</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
</tr>
<tr>
<td>Well-differentiated</td>
<td>18 (3.6%)</td>
</tr>
<tr>
<td>Moderately differentiated</td>
<td>53 (10.6%)</td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>91 (18.2%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>338 (67.6%)</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>4 (0.8%)</td>
</tr>
<tr>
<td>II</td>
<td>12 (2.4%)</td>
</tr>
<tr>
<td>III</td>
<td>58 (11.6%)</td>
</tr>
<tr>
<td>IV</td>
<td>357 (71.4%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>69 (13.8%)</td>
</tr>
</tbody>
</table>

**Table 2** Results of molecular testing

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR mutations</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>164 (32.8%)</td>
</tr>
<tr>
<td>Wild-type</td>
<td>336 (67.2%)</td>
</tr>
<tr>
<td>EML4-ALK fusion gene</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>15 (4.5%)</td>
</tr>
<tr>
<td>Wild-type</td>
<td>321 (95.5%)</td>
</tr>
</tbody>
</table>
molecular profiling as a guide for clinical treatment decisions and has paved the way for a new era of personalized treatment for NSCLC.

Studies across different ethnicities have reported the incidence of EGFR mutation in NSCLC at the rate of 10%–15% in North Americans and Europeans,23–25 10% in African-Americans,26 24% in Koreans,27 50.5% in Taiwanese,28 26.3% in Japanese,29 38.1% in Chinese,30 and 23.2% in Indian populations. Two other studies from India reported EGFR mutation frequencies of 25.9% and 51.8%, respectively, along with female dominance.13,15 Regional differences have also been reported, with a higher incidence, at 65%, in the southern Indian population as compared to 33% in northern Indian population.14,15,31–33 The incidence of EGFR mutations (32.8%) in our study is close to the reported incidence in Asian patients (47%) and much higher than that of Caucasian patients (13%).34 Our study also confirms a higher incidence of EGFR mutation in the southern Indian population (47%) as compared to the northern Indian population (27%). The incidences of EGFR mutations in eastern and western Indian populations were 33% and 26%, respectively. In the present study, a higher EGFR mutation rate was observed in females than in males (41.7% versus 28.5%; \( P=0.003 \)), and the results were found to be statistically significant. This observation is consistent with previously published studies that have shown female sex dominance in cases of EGFR mutation.14,15,36 Although we included only those patients whose tumors had been tested for EGFR mutational status, the data for NSCLC in the never-smoker population (50%) was in range of previously published reports from India (29.4% to 54.7%).14,15,37,38 The results of our study demonstrate a positive correlation of EGFR mutation in the never-smoker group as compared to smokers (43.2% versus 17.7%; \( P<0.001 \)). Overall, the results of our study are in line with the findings of other

**Figure 1** Molecular testing results. Abbreviation: NSCLC, non-small-cell lung cancer.

**Table 3** Association of each of the individual factors vis-à-vis EGFR and EML4-ALK fusion gene mutations

<table>
<thead>
<tr>
<th>Serial number</th>
<th>Variable</th>
<th>EGFR mutations</th>
<th>P-value</th>
<th>EML4-ALK fusion gene mutations</th>
<th>( \chi^2 )</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sex</td>
<td>8.7257</td>
<td>0.0031</td>
<td></td>
<td>7.2785</td>
<td>0.007</td>
</tr>
<tr>
<td>2</td>
<td>Age</td>
<td>1.1984</td>
<td>0.5493</td>
<td></td>
<td>23.635</td>
<td>0.1769</td>
</tr>
<tr>
<td>3</td>
<td>Cigarette smoking</td>
<td>29.1236</td>
<td>&lt;0.0001</td>
<td></td>
<td>3.2547</td>
<td>0.0533</td>
</tr>
<tr>
<td>4</td>
<td>Tobacco chewing</td>
<td>0.104</td>
<td>0.7471</td>
<td></td>
<td>3.3185</td>
<td>0.2344</td>
</tr>
<tr>
<td>5</td>
<td>Alcohol intake</td>
<td>1.2887</td>
<td>0.2563</td>
<td></td>
<td>3.4131</td>
<td>0.2295</td>
</tr>
<tr>
<td>6</td>
<td>Grade</td>
<td>1.5262</td>
<td>0.0221</td>
<td></td>
<td>1.1379</td>
<td>0.0176</td>
</tr>
<tr>
<td>7</td>
<td>Performance status</td>
<td>8.4289</td>
<td>0.1887</td>
<td></td>
<td>6.6411</td>
<td>0.0288</td>
</tr>
</tbody>
</table>
Indian studies, with the advantage of having data from all the four geographical regions (east, west, north, and south) of the country.

EML4 ALK fusion protein represents another molecular type, and, when inhibited by ALK and c met inhibitors in a selected subset of patients, has shown response rates of more than 60%.4 The initial reports of EML4 ALK fusion protein date back to 2007, when a few studies reported NSCLC harboring a fusion gene between EML4 and the intracellular domain of ALK.5-8 Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, hepatocyte growth factor receptor (HGFR), c-Met, and Recepteur d’Origine Nantais (RON).9 Unlike with EGFR, there are very few reports on EML4 ALK mutation across different ethnicities. The overall incidence of ALK gene rearrangements in NSCLC is estimated to be 3%, with an incidence of up to 13% in East Asian populations.5-8 Among 226 NSCLC tumor samples available in an East Asian population, the EML4-ALK fusion gene was found in about 5% of cases, mostly in young patients who were never-smokers.8 Another study, by Zhang et al reported a 13% incidence of ALK mutations in Chinese NSCLC patients, particularly in those with adenocarcinoma lacking EGFR/K-RAS mutation.6 In this study, EML4-ALK and EGFR mutations were found to be mutually exclusive, suggesting ALK mutations as a potential therapeutic target in EGFR wild-type lung cancer. A perspective review on the potential of crizotinib in NSCLC by Bang reports the prevalence of ALK fusion gene in unselected and adenocarcinoma-enriched patient populations across 14 studies as 3.4% and 4.5%, respectively.40 The total numbers of patients across 14 studies included in this review were 2,864 and 1,820 for the unselected and adenocarcinoma-enriched patient populations, respectively.

To date, there is only one published report from India on EML4 ALK mutations demonstrating a positivity of 2.7%.16 Our study confirms that EML4-ALK gene fusions are present in lung adenocarcinomas from Indian patients, and the 3% incidence of EML4-ALK gene fusion in EGFR mutation-negative cases is similar to what has been observed in other Western and Asian populations.40-42 In the present study, a higher EML4-ALK fusion gene mutation rate was observed in females than in males (9.5% versus 2.7%; P=0.009), and the results were found to be statistically significant. Age was categorized in three groups in this study, and a higher EML4-ALK fusion gene mutation rate was observed in the younger age group, of 20–40 years (P=0.006), as compared to 3.9% and 1.9% in the age groups of 40–60 years and >60 years, respectively. This finding is consistent with previously published reports on EML4 ALK fusion gene mutations.

### Conclusion

Our study reports the first multicenter data on EML4 ALK fusion gene mutations in EGFR mutation-negative Indian NSCLC patients, with the limitation of being a retrospective study that lacks survival data. However, it establishes the importance of EML4 ALK fusion gene testing in Indian NSCLC population to detect tumors harboring ALK rearrangements which can benefit from new targeted therapies. Prospective studies to investigate the survival benefit are warranted.
Acknowledgment
This study was supported by Pfizer’s Investigator Initiated Research Grant.

Disclosure
The authors report no conflicts of interest in this work. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

References

